Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05160532 · ClinicalTrials.gov registry record · Phase 2

Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis

A Phase 2 study of Knee Osteoarthritis, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
1
Study location

NCT05160532: Completed Phase 2 study of Knee Osteoarthritis, sponsored by Mayo Clinic.

NCT05160532 is a Phase 2 study of Knee Osteoarthritis that has completed, run by Mayo Clinic. The registered enrollment target is 48 participants, below the 304-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05160532, a Phase 2 study of Knee Osteoarthritis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to learn more about treating Symptomatic Knee Osteoarthritis (OA) with an ultrasound-guided hypertonic dextrose injection. Researchers would like to determine best practice for injection frequency and effectiveness of the dextrose injection for symptomatic knee OA.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Dextrose prolotherapy (DPT)

Study Locations (1)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2022-04-10
Est. Completion 2025-05-31
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT05160532

The ClinicalTrials.gov registry entry for NCT05160532 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (84% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Knee Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05160532 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT05160532 about?

NCT05160532 is a clinical study titled "Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis". The purpose of this research is to learn more about treating Symptomatic Knee Osteoarthritis (OA) with an ultrasound-guided hypertonic dextrose injection. Researchers would like to determine best practice for injection frequency and effectiveness of the dextrose injection for symptomatic knee OA.

What is the current status of trial NCT05160532?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2022-04-10. Estimated completion is 2025-05-31.

What conditions does trial NCT05160532 study?

This clinical trial studies the following conditions: Knee Osteoarthritis.

What interventions are being tested in trial NCT05160532?

The interventions under investigation include: Placebo (DRUG), Dextrose prolotherapy (DPT) (DRUG).

Who is sponsoring clinical trial NCT05160532?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05160532 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Knee Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.